Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Antibacterial effect of genetically-engineered bacteriophage ϕEf11/ϕFL1C(Δ36)PnisA on dentin infected with antibiotic-resistant Enterococcus faecalis.

Tinoco JM, Liss N, Zhang H, Nissan R, Gordon W, Tinoco E, Sassone L, Stevens R.

Arch Oral Biol. 2017 Oct;82:166-170. doi: 10.1016/j.archoralbio.2017.06.005. Epub 2017 Jun 12.

PMID:
28646693
2.

Effect of a genetically engineered bacteriophage on Enterococcus faecalis biofilms.

Tinoco JM, Buttaro B, Zhang H, Liss N, Sassone L, Stevens R.

Arch Oral Biol. 2016 Nov;71:80-86. doi: 10.1016/j.archoralbio.2016.07.001. Epub 2016 Jul 6.

3.

High Incidence of Chikungunya Virus and Frequency of Viremic Blood Donations during Epidemic, Puerto Rico, USA, 2014.

Simmons G, Brès V, Lu K, Liss NM, Brambilla DJ, Ryff KR, Bruhn R, Velez E, Ocampo D, Linnen JM, Latoni G, Petersen LR, Williamson PC, Busch MP.

Emerg Infect Dis. 2016 Jul;22(7):1221-8. doi: 10.3201/eid2207.160116. Epub 2016 Jul 15.

4.

Neutralizing Monoclonal Antibodies Block Chikungunya Virus Entry and Release by Targeting an Epitope Critical to Viral Pathogenesis.

Jin J, Liss NM, Chen DH, Liao M, Fox JM, Shimak RM, Fong RH, Chafets D, Bakkour S, Keating S, Fomin ME, Muench MO, Sherman MB, Doranz BJ, Diamond MS, Simmons G.

Cell Rep. 2015 Dec 22;13(11):2553-2564. doi: 10.1016/j.celrep.2015.11.043. Epub 2015 Dec 10.

5.

Exposure of epitope residues on the outer face of the chikungunya virus envelope trimer determines antibody neutralizing efficacy.

Fong RH, Banik SS, Mattia K, Barnes T, Tucker D, Liss N, Lu K, Selvarajah S, Srinivasan S, Mabila M, Miller A, Muench MO, Michault A, Rucker JB, Paes C, Simmons G, Kahle KM, Doranz BJ.

J Virol. 2014 Dec;88(24):14364-79. doi: 10.1128/JVI.01943-14. Epub 2014 Oct 1.

6.

A neutralizing monoclonal antibody targeting the acid-sensitive region in chikungunya virus E2 protects from disease.

Selvarajah S, Sexton NR, Kahle KM, Fong RH, Mattia KA, Gardner J, Lu K, Liss NM, Salvador B, Tucker DF, Barnes T, Mabila M, Zhou X, Rossini G, Rucker JB, Sanders DA, Suhrbier A, Sambri V, Michault A, Muench MO, Doranz BJ, Simmons G.

PLoS Negl Trop Dis. 2013 Sep 12;7(9):e2423. doi: 10.1371/journal.pntd.0002423. eCollection 2013.

7.

Characterization of the Bas-Congo virus glycoprotein and its function in pseudotyped viruses.

Steffen I, Liss NM, Schneider BS, Fair JN, Chiu CY, Simmons G.

J Virol. 2013 Sep;87(17):9558-68. doi: 10.1128/JVI.01183-13. Epub 2013 Jun 19.

8.

Mutation of the dengue virus type 2 envelope protein heparan sulfate binding sites or the domain III lateral ridge blocks replication in Vero cells prior to membrane fusion.

Roehrig JT, Butrapet S, Liss NM, Bennett SL, Luy BE, Childers T, Boroughs KL, Stovall JL, Calvert AE, Blair CD, Huang CY.

Virology. 2013 Jul 5;441(2):114-25. doi: 10.1016/j.virol.2013.03.011. Epub 2013 Apr 6.

9.

A small animal peripheral challenge model of yellow fever using interferon-receptor deficient mice and the 17D-204 vaccine strain.

Thibodeaux BA, Garbino NC, Liss NM, Piper J, Blair CD, Roehrig JT.

Vaccine. 2012 May 2;30(21):3180-7. doi: 10.1016/j.vaccine.2012.03.003. Epub 2012 Mar 13.

10.

A humanized IgG but not IgM antibody is effective in prophylaxis and therapy of yellow fever infection in an AG129/17D-204 peripheral challenge mouse model.

Thibodeaux BA, Garbino NC, Liss NM, Piper J, Schlesinger JJ, Blair CD, Roehrig JT.

Antiviral Res. 2012 Apr;94(1):1-8. doi: 10.1016/j.antiviral.2012.02.001. Epub 2012 Feb 15.

11.

Development of a human-murine chimeric immunoglobulin M for use in the serological detection of human alphavirus antibodies.

Thibodeaux BA, Liss NM, Panella AN, Roehrig JT.

Clin Vaccine Immunol. 2011 Dec;18(12):2181-2. doi: 10.1128/CVI.05269-11. Epub 2011 Oct 5.

12.

[PSI+] maintenance is dependent on the composition, not primary sequence, of the oligopeptide repeat domain.

Toombs JA, Liss NM, Cobble KR, Ben-Musa Z, Ross ED.

PLoS One. 2011;6(7):e21953. doi: 10.1371/journal.pone.0021953. Epub 2011 Jul 8.

13.

[Morphological changes in the endometrium of women using an intrauterine contraceptive device].

Grishchenko VI, Iakovtsova AF, Liss NL, Titarenko LE, Ofitserov VN.

Akush Ginekol (Mosk). 1980 Mar;(3):41-2. Russian.

PMID:
7377499
14.

[Unithiol therapy of patients with secondary amyloidosis (preliminary report)].

Dubinskiĭ AA, Bondarenko IP, Iakovtsova AF, Liss ND, Postnikov AV.

Ter Arkh. 1980;52(8):122-4. Russian. No abstract available.

PMID:
7256578

Supplemental Content

Support Center